Information:
Error:
ID
36386
Description
Study of ESR1 Mutations in Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02473120
Link
https://clinicaltrials.gov/show/NCT02473120
Keywords
Versions (1)
- 5/9/19 5/9/19 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
May 9, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Metastatic Breast Cancer NCT02473120
Eligibility Metastatic Breast Cancer NCT02473120
- StudyEvent: Eligibility
Similar models
Eligibility Metastatic Breast Cancer NCT02473120
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Gender | Age
Item
woman aged superior to 18 years old
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Informed Consent
Item
inform consent signed
boolean
C0021430 (UMLS CUI [1])
Secondary malignant neoplasm of female breast | Advanced breast cancer Local-Regional
Item
metastatic breast cancer or loco-regionnaly advanced breast cancer
boolean
C0346993 (UMLS CUI [1])
C3495917 (UMLS CUI [2,1])
C1947913 (UMLS CUI [2,2])
C3495917 (UMLS CUI [2,1])
C1947913 (UMLS CUI [2,2])
Inoperable
Item
inoperable
boolean
C0205187 (UMLS CUI [1])
Indication Aromatase Inhibitors
Item
with an indication to treat with aromatase inhibitor
boolean
C3146298 (UMLS CUI [1,1])
C0593802 (UMLS CUI [1,2])
C0593802 (UMLS CUI [1,2])
Aromatase Inhibitors Initiation | Stable Disease
Item
treatment with aromatase inhibitors innitiated at the inclusion or at least 6 months before inclusion with a stable disease
boolean
C0593802 (UMLS CUI [1,1])
C1704686 (UMLS CUI [1,2])
C0677946 (UMLS CUI [2])
C1704686 (UMLS CUI [1,2])
C0677946 (UMLS CUI [2])
Prior Therapy Absent | Chemotherapy | Tamoxifen | Faslodex | Aromatase Inhibitors | Adjuvant therapy
Item
without precedent treatment or with treatment by chemotherapy/tamoxifen/faslodex or aromatase inhibitors in a adjuvant treatment and with a time frame of 2 years between last treatment with aromatase inhibitors and metastatic evolution
boolean
C1514463 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2])
C0039286 (UMLS CUI [3])
C0701491 (UMLS CUI [4])
C0593802 (UMLS CUI [5])
C0677850 (UMLS CUI [6])
C0332197 (UMLS CUI [1,2])
C0392920 (UMLS CUI [2])
C0039286 (UMLS CUI [3])
C0701491 (UMLS CUI [4])
C0593802 (UMLS CUI [5])
C0677850 (UMLS CUI [6])
Aromatase Inhibitors alone | Aromatase Inhibitors Combination Targeted Therapy | trastuzumab | pertuzumab | bevacizumab | everolimus
Item
treatment by aromatase inhibitors alone or in combination with a targeted therapy (trastuzumab +/- pertuzumab, bevacizumab, everolimus)
boolean
C0593802 (UMLS CUI [1,1])
C0205171 (UMLS CUI [1,2])
C0593802 (UMLS CUI [2,1])
C0205195 (UMLS CUI [2,2])
C2985566 (UMLS CUI [2,3])
C0728747 (UMLS CUI [3])
C1328025 (UMLS CUI [4])
C0796392 (UMLS CUI [5])
C0541315 (UMLS CUI [6])
C0205171 (UMLS CUI [1,2])
C0593802 (UMLS CUI [2,1])
C0205195 (UMLS CUI [2,2])
C2985566 (UMLS CUI [2,3])
C0728747 (UMLS CUI [3])
C1328025 (UMLS CUI [4])
C0796392 (UMLS CUI [5])
C0541315 (UMLS CUI [6])
Informed Consent Lacking
Item
no inform consent signed
boolean
C0021430 (UMLS CUI [1,1])
C0332268 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,2])
Patient Guardianship
Item
patient under guardianship, curatorship
boolean
C0030705 (UMLS CUI [1,1])
C0870627 (UMLS CUI [1,2])
C0870627 (UMLS CUI [1,2])
Psychosocial problem
Item
psychosocial disorder
boolean
C0740697 (UMLS CUI [1])
Social insurance Lacking
Item
no affiliated or beneficiary of a social benefit system
boolean
C0037435 (UMLS CUI [1,1])
C0332268 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,2])